We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

APOE Genotype and Brain Development

John H. Growdon, MD1; Bradley T. Hyman, MD, PhD1
[+] Author Affiliations
1Neurology Service, Massachusetts General Hospital, Boston
JAMA Neurol. 2014;71(1):7-8. doi:10.1001/jamaneurol.2013.5200.
Text Size: A A A
Published online


The observation that inheritance of the apolipoprotein E (APOE) ε4 allele predisposes dramatically to Alzheimer disease (AD) was first reported in 19931 and has been replicated in hundreds of studies thereafter. It is one of the most robust genetic associations with common disease discovered in all of medicine, yet despite 20 years of research, the reason that APOE ε4 has such a profound increase of risk in AD remains uncertain. Several facts are clear: (1) the APOE ε4 genotype predisposes toward AD pathology, primarily with amyloid deposits2; (2) the predisposition is relatively specific because the effect of the APOE ε4 genotype on other neurodegenerative diseases is either minimal or absent3; (3) the APOE ε4 genotype predisposes toward an earlier age at onset of AD dementia2,4 and appears to be additive in this effect of earlier age at onset even in the presence of other AD-predisposing genes like PS1 or even Down syndrome; and (4) the APOE ε4 genotype is associated with diminished glucose metabolism in posterior brain regions in a pattern characteristic of AD even in healthy, nondemented individuals.5 The article by Dean et al6 in this issue builds on these observations that the APOE ε4 genotype is associated with an early cerebral blood flow phenotype even in middle-aged individuals at risk for AD and asks just how early in the life span an APOE ε4 effect on the brain can be observed. They carried out an observational study on infants between the ages of 2 and 25 months and astonishingly found evidence for morphological changes in brain areas that would be susceptible for AD-related neuropathological changes decades later. Specifically, among ε4 carriers, gray matter volume and myelin water fraction were lower in the precuneus, posterior and middle cingulate, and lateral temporal and medial occipitotemporal regions than in ε4 noncarriers, whereas these measures were greater in frontal regions. These observations prompted Dean et al to speculate that the APOE ε4 genotype is a more powerful genetic predeterminant of AD than previously expected. The results also raise intriguing questions about just “when” AD-related brain alterations might be considered to start.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections